MetaCap

OPKO Health Financial Ratios

NASDAQ: OPKHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.38+0.01 (+0.73%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

OPKO Health ratio analysis

OPKO Health earned a net margin of -37.2% in FY 2025, down from -7.5% a year earlier. Gross margin was 33.9% compared with a median of 36.8% over the prior 5 years. Return on equity reached -17.8%, meaning OPKO Health generated -0.18 dollars of profit for every dollar of shareholders' equity.

Debt-to-equity stood at 0.00 versus 0.32 the year before, and the current ratio was 3.97. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.

Summary generated from market data by MetaCap's automated system. Methodology

OPKO Health financial ratios (annual)

OPKO Health annual financial ratios
RatioFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
P/E ratio (at fiscal year end)—————79.00————
Price / sales1.571.441.310.901.761.760.972.012.844.58
Price / book0.750.750.820.581.851.510.541.111.492.50
Gross margin33.9%30.6%36.8%28.7%————93.7%49.5%
Operating margin-19.3%-21.3%-18.2%-22.5%1.1%4.0%-30.4%-17.3%-28.6%-8.6%
Net margin-37.2%-7.5%-21.9%-32.7%-1.7%2.1%-34.9%-15.5%-31.6%-4.3%
Free cash flow margin-31.4%-29.2%-5.2%-11.9%0.3%0.4%-20.5%-13.8%-14.3%1.2%
Return on equity (ROE)-17.8%-3.9%-13.6%-21.0%-1.8%1.8%-19.5%-8.5%-16.6%-2.4%
Return on assets (ROA)-11.7%-2.4%-9.4%-15.2%-1.3%1.2%-13.6%-6.2%-11.8%-1.7%
Debt / equity0.000.320.010.010.000.000.000.010.010.01
Current ratio3.973.431.551.852.491.391.301.101.121.84
Revenue growth-14.9%-17.4%-14.0%-43.4%23.6%59.1%-8.9%2.5%-13.6%127.3%
EPS growth————-200.0%—————

Related